



Case Report

Benefits of Inspiratory Muscle Training in Myotonic Dystrophy: A Case Report

Charlotte G.W. Seijger^{a,*}, Jellie Nieuwenhuis^a, Baziel G.M. van Engelen^b, Peter J. Wijkstra^a

^a Department of Pulmonary Diseases and Home Mechanical Ventilation, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands

^b Department of Neurology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen, Radboudumc, Nijmegen, The Netherlands



We present a Myotonic Dystrophy type 1 (DM1) patient with nocturnal alveolar hypoventilation, who performed twelve weeks of inspiratory muscle training (IMT).

A 54-year-old DM1 male, classical phenotype, visited the outpatient-clinic because of progressive fatigue and dyspnoea. Pulmonary function was stable with reduced forced vital capacity of 3.2 L (64%) and severely reduced maximum inspiratory muscle strength (PImax) of 17.95 cmH₂O (19.7%). A nocturnal

transcutaneous gas-exchange measurement showed a median of P_{tcCO_2} 6.6 kPa (49.5 mmHg) and four episodes of 30 min hypoventilation (probably REM sleep related), with deep oxygen desaturations of 80% and P_{tcCO_2} increases to 7.5 kPa (56.3 mmHg). While he was placed on the waiting list for initiation of non-invasive home mechanical ventilation (HMV), he started a 12 week home based IMT programme, after written informed consent. During this period he did not start with HMV, nor other modifica-




Fig. 1. Transcutaneous measured nocturnal gas-exchange with SenTec before and after 12 weeks of IMT. Blue colour lines indicate measurement before IMT, orange colour lines after IMT. The top row visualizes P_{tcCO_2} (kPa), the middle row the saturation (%) and the bottom row the pulse rate (PR) in bpm.

* Corresponding author.

E-mail address: c.g.w.seijger@umcg.nl (C.G.W. Seijger).

tions in treatment were made. Based on positive effects of IMT in neuromuscular disorders and of general exercise training in DM1, we hypothesized that IMT could improve his weakened respiratory muscles and respiration.^{1–3} Training programme consisted of two sessions per day at five days a week. He used an electronic POWERbreathe KHP2 device (Hab international, Southam, UK) and wear a nose clip. One session included 30 inspirations against resistance, started on 30% of baseline PI_{max} (5 cmH₂O). The resistance was increased every two weeks during a supervised training, based on patients' highest tolerable intensity, which was confirmed with stable real-life inspiratory flow measurements using a POWERbreathe KH2 device and associate software.

Power and inspiratory endurance capacity of breathing muscles ameliorated significantly. PI_{max} improved with 176% to 47.94 cmH₂O (52%) and inspiratory endurance capacity increased from 187 s. on a resistance of 7 cmH₂O to 305 s. on 19 cmH₂O. The effects on nocturnal gas-exchange are visualized in Fig. 1. Compared to baseline both oxygenation and ventilation improved. Mean saturation increases from 93% to 95% and hypercapnia decreases from a median P_{tcCO_2} of 6.6 kPa (49.5 mmHg) to 6.2 kPa (46.5 mmHg). The four P_{tcCO_2} peaks are lowered, accompanied by less deep desaturations and steady heart rate frequency. Forced vital capacity remained stable with 3.2 L. IMT resistance was gradually increased every two weeks as follows: 5–7–12–17–21 cmH₂O to a maximum of 26 cmH₂O. He fulfilled all prescribed exercises, which were well tolerated without side effects. Afterwards, he reported improvement in his speech. MRC dyspnoea score improved from 4 to 3 points and health-related quality of life score measured on the Severe Respiratory Insufficiency questionnaire improved from 55 to 61 points.⁴

Respiratory muscle weakness is the main reason for life-threatening pneumonia and respiratory failure, which are primary

causes of death at a mean age of 54 years.⁵ Current treatment for chronic hypercapnic respiratory failure is HMV, which is a high-burden and expensive treatment with usually a low adherence in DM1.⁶ To the opposite, IMT is a low-burden therapy with negligible risks, low costs and positive effects in 951 patients with several neuromuscular disorders, although DM1 was not included.² This case adds to the existing evidence that DM1 can respond favourably to IMT, as well. Especially the benefits on hypercapnia are promising. It warrants further investigations, whether IMT could improve respiration in order to become a complementary treatment with HMV in DM1 patients.

Conflict of interest

None.

References

1. Mackenzie SJ, Hamel J, Thornton CA. Benefits of aerobic exercise in myotonic dystrophy type 1. *J Clin Invest*. 2022;132:1–3.
2. Watson K, Egerton T, Sheers N, Retica S, McGaw R, Clohessy T, et al. Respiratory muscle training in neuromuscular disease: a systematic review and meta-analysis. *Eur Respir Rev*. 2022;31:1–23.
3. de Freitas Fregonezi GA, Resqueti VR, Casan P. Domiciliary respiratory muscle training in myotonic dystrophy. *Arch Bronconeumol*. 2006;42:605–7.
4. Windisch W, Freidel K, Schucher B, Baumann H, Wiebel M, Matthys H, et al. The Severe Respiratory Insufficiency (SRI) Questionnaire – a specific measure of health-related quality of life in patients receiving home mechanical ventilation. *J Clin Epidemiol*. 2003;56:752–9.
5. Mathieu J, Allard P, Potvin L, Prévost C, Bégin P. A 10-year study of mortality in a cohort of patients with myotonic dystrophy. *Neurology*. 1999;52:1658–62.
6. Vosse BAH, Seijger C, Cobben N, van Engelen B, van Kuijk SMJ, Faber C, et al. Noninvasive home mechanical ventilation in adult myotonic dystrophy type 1: a systematic review. *Respiration*. 2021;100:816–25.